Fertility Supplements That Actually Work: Top Picks Ranked

Fertility Supplements That Actually Work: What the Research Says (2026)

The fertility supplement market is a $3+ billion industry built on an uncomfortable fact: most products in it have little or no human clinical trial evidence for fertility specifically. Between ingredients with robust RCT data and those with nothing but in-vitro studies or animal data lies a huge commercial space filled with marketing claims. This guide cuts through it.

We reviewed the peer-reviewed evidence across fertility-relevant supplements and assigned each an evidence tier based on study design, sample size, replication, and endpoint relevance to human fertility. The result: a clear picture of what works, what has potential, and what is supported primarily by marketing.

Note: “Fertility supplement” is a broad term. This review covers supplements with evidence for the most clinically important fertility endpoints: ovulation rate, egg quality, sperm parameters (count/motility/morphology), IVF clinical pregnancy rate, and live birth rate. Libido, “reproductive wellness,” and animal-model-only data are not used as evidence proxies for these endpoints.

How We Grade Evidence

Supplements With Strong Evidence (Level 1)

Methylfolate / Folic Acid — Women (Universal)

Evidence Tier: Level 1 — Mandatory Recommendation

Folate has the strongest and most consistent evidence base of any supplement in reproductive medicine. The MRC Vitamin Study Research Group (Lancet, 1991, PMID: 1677062) conducted a landmark multi-center RCT of periconceptional folic acid supplementation and found a 72% reduction in recurrence of neural tube defects in supplemented women. Subsequent population-level data have replicated this finding across multiple countries.

Beyond neural tube prevention, Chavarro et al. (Archives of Internal Medicine, 2008, PMID: 18541822) found higher dietary folate associated with significantly lower ovulatory infertility risk in a prospective cohort of 18,000 women — a fertility benefit independent of NTD protection.

The methylfolate vs. folic acid question: Approximately 30–40% of women have MTHFR gene variants that impair conversion of synthetic folic acid to active 5-methyltetrahydrofolate (5-MTHF). These women may not achieve adequate active folate levels on folic acid alone. Methylfolate supplements (Thorne 5-MTHF, Pure Encapsulations Folate) deliver the bioactive form directly.

Effective dose: 400–800mcg/day methylfolate, starting 3–6 months before conception.

Bottom line: Non-negotiable for all women attempting conception. Start it first.

Myo-Inositol — Women with PCOS (Level 1)

Evidence Tier: Level 1 — Strong for PCOS Population

Myo-inositol has been evaluated in multiple double-blind RCTs for PCOS-related infertility. The landmark comparator trial (Unfer et al., Gynecological Endocrinology, 2012, PMID: 21721931) randomized PCOS women undergoing IVF to myo-inositol 4g/day vs. metformin 1,500mg/day. Myo-inositol produced equivalent clinical pregnancy rates with significantly fewer gastrointestinal side effects. A 2017 meta-analysis (Monastra et al.) confirmed non-inferiority of myo-inositol vs. metformin for ovulation induction in PCOS.

For the 40:1 combination with D-chiro-inositol: Unfer et al. (2016, Endocrine, PMID: 27600526) published a systematic review confirming superior hormonal outcomes (testosterone, LH/FSH ratio) with the combination versus myo-inositol alone.

Effective dose: 4g myo-inositol/day (2g twice daily), optionally at 40:1 ratio with D-chiro-inositol (50mg DCI per dose).

Bottom line: Highest-evidence PCOS fertility intervention outside of medical treatment. Non-inferior to metformin in RCTs. Best used as the 40:1 combination for women pursuing IVF or egg quality optimization.

CoQ10 (Ubiquinol) — Men and Women (Level 1)

Evidence Tier: Level 1 — Strong for Male Infertility; Strong for Female IVF (DOR)

Male fertility: A 2013 meta-analysis (Lafuente et al., Journal of Urology, PMID: 23414678) of RCTs found CoQ10 supplementation significantly improved sperm concentration, motility, and morphology in infertile men versus placebo. Balercia et al. (2009) found 300mg CoQ10/day for 26 weeks significantly improved sperm motility as the primary endpoint in men with idiopathic asthenospermia.

Female fertility: Bentov et al. (Fertility and Sterility, 2014, PMID: 24388466) found CoQ10 600mg/day for 2 months significantly improved oocyte quality and embryo chromosomal normalcy in women with diminished ovarian reserve. A 2020 meta-analysis (Reproductive Biology and Endocrinology, Xu et al., PMID: 32907594) found higher clinical pregnancy rates with CoQ10 in IVF. Mechanistically, CoQ10 directly addresses mitochondrial dysfunction — the established driver of age-related oocyte quality decline.

Effective dose: 200–300mg/day ubiquinol for men (3 months); 400–600mg/day ubiquinol for women over 35 or DOR (start 3 months before retrieval). Use ubiquinol form, not ubiquinone, for adults over 35.

Bottom line: Best-evidence supplement for both sperm motility and egg quality. Prioritize for men with motility issues and women over 35.

Zinc — Men (Level 1)

Evidence Tier: Level 1 — Strong for Male Subfertility

A systematic review (Fallah et al., Journal of Reproduction & Infertility, 2018, PMID: 29657843) confirmed zinc supplementation significantly improved sperm count, motility, and testosterone in infertile men with below-normal zinc status. Wong et al. (Fertility and Sterility, 2002) found zinc supplementation significantly increased sperm count, motility, and fertilizing capacity in a double-blind RCT. Mechanistically, zinc is essential to every stage of spermatogenesis — from germ cell proliferation to epididymal sperm maturation — and inhibits aromatase, maintaining testosterone levels.

Effective dose: 25–30mg/day zinc picolinate or glycinate. Do not exceed 40mg/day without supervision (copper depletion at high chronic doses).

L-Carnitine — Men (Level 1)

Evidence Tier: Level 1 — Strong for Sperm Motility

L-carnitine is concentrated in the epididymis at extremely high levels and is essential for long-chain fatty acid transport into sperm mitochondria — the energy source for flagellar motion. Lenzi et al. (Fertility and Sterility, 2004, PMID: 15193482) found L-carnitine (2g/day) + acetyl-L-carnitine (1g/day) significantly improved total and forward motility in men with asthenospermia in a double-blind RCT. A 2012 systematic review identified L-carnitine as the supplement with the most consistent evidence for improving sperm motility specifically.

Effective dose: 2–3g L-carnitine/day ± 1–2g acetyl-L-carnitine for 3–6 months. Lower doses show less consistent benefit.

Supplements With Moderate Evidence (Level 2)

Vitamin D — Women and Men

Evidence Tier: Level 2 — Moderate

A 2017 meta-analysis (Human Reproduction Update, Chu et al., PMID: 28586196) found women with vitamin D sufficiency (≥30 ng/mL) had significantly higher clinical pregnancy rates and live birth rates from IVF. However, many studies are observational — confounded by the fact that overall health status predicts both vitamin D levels and fertility outcomes. Intervention trials are limited. For men, vitamin D supplementation has been found to improve testosterone levels and sperm motility in vitamin D-deficient men (Pilz et al., 2011, Hormone and Metabolic Research).

Effective dose: Test serum 25(OH)D; correct deficiency to 40–60 ng/mL with 2,000–5,000 IU/day. Pair with vitamin K2 (100mcg MK-7). Benefit is primarily in correcting deficiency; evidence for supranormal dosing in fertility-sufficient individuals is limited.

Selenium — Men

Evidence Tier: Level 2 — Moderate

Scott et al. (1998, PMID: 9634040) found selenium supplementation (100mcg/day) for 3 months significantly improved sperm motility in Scottish men with deficient baseline selenium. A 2009 RCT found selenium + NAC combination reduced sperm DNA fragmentation and improved sperm parameters. However, evidence is primarily in deficient populations, and there are selenium-toxicity concerns at higher doses.

Effective dose: 100–200mcg/day selenomethionine; do not exceed 400mcg/day.

Omega-3 (EPA + DHA) — Both Partners

Evidence Tier: Level 2 — Moderate

A 2018 prospective cohort study (JCEM) found higher omega-3 intake associated with greater probability of achieving pregnancy in women undergoing ART. For men, omega-3 supplementation has been found to improve sperm morphology and reduce DNA fragmentation in observational and small RCT data. DHA is the primary structural fatty acid in the sperm midpiece and sperm head acrosome.

Effective dose: 1–2g/day EPA+DHA (triglyceride form fish oil or algal DHA).

Ashwagandha (KSM-66) — Men

Evidence Tier: Level 1 for Male Fertility Specifically

Ambiye et al. (2013, PMID: 24371462) found KSM-66 675mg/day for 90 days produced a 167% increase in sperm count, 57% increase in motility, and 17% increase in serum testosterone in oligospermic men versus placebo in a double-blind RCT. The mechanism is testosterone normalization through HPA axis modulation and reduced cortisol-driven gonadotropin suppression. Evidence for female fertility is mechanistically indirect — stress reduction may support reproductive hormone balance, but direct female fertility RCTs are lacking.

Supplements Without Meaningful RCT Evidence for Fertility

Supplement Evidence Summary Table

Building a Fertility Supplement Protocol

For women (general): Methylfolate (start first, 3–6 months before), Vitamin D3 (test first), CoQ10 ubiquinol 400mg/day (start 3 months before), Omega-3 DHA 1–2g/day.

For women with PCOS: Add myo-inositol at 40:1 combination 4g/day to the above.

For women 35+ or with DOR: Increase CoQ10 to 600mg/day ubiquinol; DHEA under physician supervision.

For men: CoQ10 ubiquinol 200–300mg/day, zinc picolinate 30mg/day, ashwagandha KSM-66 600mg/day, L-carnitine 2g/day + ALCAR 1g/day, selenium 200mcg/day.

For both partners: Vitamin D3 correction (test first), omega-3 EPA+DHA.

Start the full protocol 3 months before planned conception attempt or IVF cycle start. Reassess after 3 months with repeat semen analysis (male) and ovarian reserve labs if applicable (female).

Final Verdict

The fertility supplements with the clearest RCT evidence are: methylfolate (universal for women), myo-inositol (PCOS population), CoQ10 ubiquinol (both sexes), zinc (men), L-carnitine (men with motility issues), and ashwagandha KSM-66 (men with low count/testosterone). These are the supplements worth prioritizing.

Vitamin D and omega-3 warrant inclusion based on prevalence of deficiency and moderate evidence — prioritized when testing confirms insufficiency.

The broad category of “fertility blends” and herbal fertility products sold without peer-reviewed clinical evidence should be approached with significant skepticism. Budget and attention are better directed toward the evidence-backed compounds at their studied doses.

Related Reading

• Best Fertility Supplements for Women — complete ranked guide for female fertility supplementation
• Best Male Fertility Supplements — zinc, CoQ10, L-carnitine, selenium, ashwagandha ranked
• Myo-Inositol vs D-Chiro-Inositol for PCOS — complete comparison guide
• Best Prenatal Vitamins 2026 — comprehensive preconception and pregnancy multivitamin coverage

Evidence base: MRC Vitamin Study Research Group (1991), Lancet, PMID: 1677062; Chavarro JE et al. (2008), Arch Intern Med, PMID: 18541822; Unfer V et al. (2012), Gynecol Endocrinol, PMID: 21721931; Monastra G et al. (2017), Gynecol Endocrinol; Lafuente R et al. (2013), J Urol, PMID: 23414678; Balercia G et al. (2009), Fertil Steril, PMID: 18249210; Bentov Y et al. (2014), Fertil Steril, PMID: 24388466; Xu Y et al. (2020), Reprod Biol Endocrinol, PMID: 32907594; Fallah A et al. (2018), J Reprod Infertil, PMID: 29657843; Lenzi A et al. (2004), Fertil Steril, PMID: 15193482; Ambiye VR et al. (2013), Evid-Based Complement Altern Med, PMID: 24371462; Chu J et al. (2017), Hum Reprod Update, PMID: 28586196; Scott R et al. (1998), BJU, PMID: 9634040.